Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome

Abstract

The present invention provides a prophylactic or therapeutic agent for irritable bowel syndrome, which comprises a compound represented by formula (I): wherein, R 1 represents an optionally substituted hydrocarbon group, etc., R 2 represents a hydrogen atom or an optionally substituted hydrocarbon group, R 3 represents a hydrogen atom, an optionally substituted hydrocarbon group, etc., X represents CHR 4 , NR 4 , CO, O or S (wherein, R 4 represents a hydrogen atom, an optionally substituted hydrocarbon group, etc.), Y represents C, CH or N, represents a single bond or double bond, ring A represents an optionally substituted 5- to 7-membered oxygen-containing heterocyclic ring, ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof.

1 . A pharmaceutical composition for a prevention or treatment of irritable bowel syndrome, which comprises a compound represented by formula (I): 
     
       
         
         
             
             
         
       
       wherein, R 1  represents an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, 
       R 2  represents a hydrogen atom or an optionally substituted hydrocarbon group, 
       R 3  represents a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, 
       X represents CHR 4 , NR 4 , CO, O or S (wherein, R 4  represents a hydrogen atom, an optionally substituted hydrocarbon group or hydroxyl group), 
       Y represents C, CH or N, 
          represents a single bond or double bond, 
       ring A represents an optionally substituted 5- to 7-membered heterocyclic ring containing an oxygen atom, 
       ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof. 
     
   
   
       2 . The pharmaceutical composition for a prevention or treatment of irritable bowel syndrome according to  claim 1 , wherein the compound represented by formula (I) or a salt thereof is (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide. 
   
   
       3 . A method for a prevention or treatment of irritable bowel syndrome, which comprises administering an effective amount of a compound represented by formula (I): 
     
       
         
         
             
             
         
       
       wherein, R 1  represents an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, 
       R 2  represents a hydrogen atom or an optionally substituted hydrocarbon group, 
       R 3  represents a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, 
       X represents CHR 4 , NR 4 , CO, O or S (wherein, R 4  represents a hydrogen atom, an optionally substituted hydrocarbon group or hydroxyl group), 
       Y represents C, CH or N, 
          represents a single bond or double bond, 
       ring A represents an optionally substituted 5- to 7-membered heterocyclic ring containing an oxygen atom, 
       ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof. 
     
   
   
       4 . The method for a prevention or treatment according to  claim 3 , wherein the compound represented by formula (I) or a salt thereof is (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide. 
   
   
       5 . Use of a compound represented by formula (I): 
     
       
         
         
             
             
         
       
       wherein, R 1  represents an optionally substituted hydrocarbon group, an optionally substituted amino group or an optionally substituted heterocyclic group, 
       R 2  represents a hydrogen atom or an optionally substituted hydrocarbon group, 
       R 3  represents a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, 
       X represents CHR 4 , NR 4 , CO, O or S (wherein, R 4  represents a hydrogen atom, an optionally substituted hydrocarbon group or hydroxyl group), 
       Y represents C, CH or N, 
          represents a single bond or double bond, 
       ring A represents an optionally substituted 5- to 7-membered heterocyclic ring containing an oxygen atom, 
       ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof, for the manufacture of a pharmaceutical composition for a prevention or treatment of irritable bowel syndrome. 
     
   
   
       6 . The use according to  claim 5 , wherein the compound represented by formula (I) or a salt thereof is (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.